Navigation Links
Omeros Unlocks Four Additional Orphan GPCRs
Date:9/13/2011

l libraries using its proprietary, high-throughput cellular redistribution assay (CRA). Omeros has announced that it has identified and confirmed sets of compounds that interact selectively with 14 orphan receptors linked to esophageal squamous cell carcinoma and obesity-related type-2 diabetes (GPR39), squamous cell carcinoma (GPR87), pancreatic cancer (GPR182), acute lymphoblastic leukemia (P2Y8/P2RY8), sleep disorders (OPN4), cognitive disorders (GPR12), bipolar disorder and schizophrenia (GPR78), psychotic and metabolic disorders (GPR27, GPR85, GPR173), appetite control (GPR101), rheumatoid arthritis and HIV-mediated enteropathy (GPR15), motor control (GPR139) and congenital cataracts and birth defects of the brain and spinal cord (GPR161). The CRA detects receptor antagonists and agonists. Antagonists comprise the majority of marketed drugs, and all of the compounds characterized so far by Omeros are antagonists.

About G Protein-Coupled Receptors

GPCRs, which mediate key physiological processes in the body, are one of the most valuable families of drug targets. According to Insight Pharma Reports, GPCR-targeting drugs represent 30 to 40 percent of marketed pharmaceuticals. Examples include Claritin® (allergy), Zantac® (ulcers and reflux), OxyContin® (pain), Lopressor® (high blood pressure), Imitrex® (migraine headache), Reglan® (nausea) and Abilify® (schizophrenia, bipolar disease and depression) as well as all other antihistamines, opioids, alpha and beta blockers, serotonergics and dopaminergics.  

The industry focuses its GPCR drug discovery efforts mostly on non-sensory GPCRs. Of the 363 total non-sensory GPCRs, approximately 240 have known ligands (molecules that bind the receptors) with nearly half of those targeted either by marketed drugs (46 GPCRs) or by drugs in development (about 70 GPCRs). There are approximately 120 GPCRs with no known ligands, which are termed "orphan GPCRs." Wit
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Omeros Unlocks Orphan GPCRs Linked to Leukemia and Sleep Disorders
2. Omeros Reports Allowance of Additional Patent for Arthroscopic Product
3. Omeros Announces Clinical Development Programs for OMS103HP and OMS302
4. Omeros Corporation Reports First Quarter 2011 Financial Results
5. Omeros Announces Expansion of Potential Indications for PDE7 Inhibitors
6. Omeros Announces Publication of MASP-2 Data in Proceedings of the National Academy of Sciences
7. Omeros Reports Outcome of Phase 3 Trials of OMS103HP
8. Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results
9. Omeros Unlocks Orphan GPCRs Linked to Pancreatic Cancer and Cognitive Disorders
10. Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo
11. Omeros Announces Publication of Data From Antifibrinolytic Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... May 17, 2013  Sanofi (EURONEXT: SAN and NYSE: ... JAKARTA , examining the selective JAK2 ... in both dose groups. The primary endpoint assessed the ... Consistent with data reported in previous trials, the most ... Full results will be presented at an upcoming medical ...
(Date:5/16/2013)... ZURICH , May 17, 2013 ... and Research (A*STAR) and Switzerland,s Cytos ... been dosed in a Phase 1 clinical trial with their ... virus-like particle (VLP) technology. In this first Phase 1 clinical ... and its potential to protect against H1N1 influenza infection will ...
(Date:5/16/2013)... 16, 2013  Today, the National Patient Advocate Foundation ... House of Representatives recently approved a bill that would ... patients higher out-of-pocket fees for newer, more expensive oral ... have more severe side-effects. However, the bill was amended ... will continue to be a barrier to patients with ...
Breaking Medicine Technology:Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 2National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 3
(Date:5/19/2013)... 2013 People in Minnesota have a great ... is offering its 28 Day Fat Loss Formula. The ... comfort of their own home. The product sells for $135 ... can be accessed here: http://altmanfitness.com/28-day-fat-loss-formula/ , “Bikini season ... houses now, but after using the 28 Day Fat Loss ...
(Date:5/19/2013)... May 19, 2013 The muscles in ... their functionality and one of the biggest and most ... nervous system. The peripheral system comprises of peripheral nerves ... cord. These nerves ensure that the limbs and hands, ... when these nerves get damaged due to trauma or ...
(Date:5/19/2013)... According to a new market research report ... 2018): By Applications (Healthcare (Endoscopy, Radiology, Ophthalmology), Surveillance, ... IS, Infrared, X-Ray) And Geography" published by MarketsandMarkets, ... billion in 2012 and is expected to reach ... of 3.84% from 2013 to 2018. In terms ...
(Date:5/19/2013)... May 19, 2013 The report “Feed ... Trends & Forecasts up to 2017” published by MarketsandMarkets, ... with analysis and forecasting of the global volume and ... the driving and restraining factors for the global market ... and challenges. The market is segmented and revenue is ...
(Date:5/19/2013)... Americans live closer to their dogs than ever ... Association (AVMA) U.S. Pet Ownership and Demographics Sourcebook, more ... a member of the family, up from the 53.5% ... earlier. , According to the American Pet Products Association, ... to pets has increased every year without interruption, including ...
Breaking Medicine News(10 mins):Health News:Ultimate Neuropathy Support System Launched by Neuracel - Reaching New Heights in Herbal Medication for Peripheral Neuropathy 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 3Health News:Feed Additives Market to Reach $19.5 Billion by 2017 at a CAGR of 3.8% - New Report by MarketandMarkets 2Health News:Feed Additives Market to Reach $19.5 Billion by 2017 at a CAGR of 3.8% - New Report by MarketandMarkets 3Health News:Dogs Becoming Part of the Family: Dog Bite Injuries Decreasing 2Health News:Dogs Becoming Part of the Family: Dog Bite Injuries Decreasing 3
... A consortium of federal agencies and nongovernmental organizations has ... and data-collection methods for use in asthma clinical research. ... Outcomes Workshop, which appears as a supplement to the ... and Clinical Immunology , resulted from a meeting organized ...
... FRIDAY, March 2 (HealthDay News) -- Women become less likely ... first year of college, new research finds. Declining condom ... had worse grades and who came from poorer backgrounds. ... unplanned pregnancies and sexually transmitted diseases, yet there has been ...
... people who consume drugs containing cannabinoid compounds found in ... Marsicano (Inserm Research Unit 862) in collaboration with a ... mechanism by which these substances affect working memory. These ... adverse effect of cannabinoids on working memory is exerted ...
... in childhood have a higher risk of infertility in ... Balcerek and her co-authors in a study published in ... 109[7] 126-31). , In a nationwide German survey on ... the authors collected data from former pediatric oncology patients. ...
... By Steven Reinberg HealthDay Reporter , THURSDAY, March ... to screen for cervical cancer are more likely to survive ... Swedish study suggests. Compared to women whose cervical cancer ... Pap smear increased their cure rate from 66 percent to ...
... news for the 27,000 plus people around the world who ... living kidney donors for 10 years found that they were ... general population. Led by Dr. Amit Garg, ... London Health Sciences Centre, the results provide important safety reassurances ...
Cached Medicine News:Health News:Standardized outcome measures proposed for asthma clinical research 2Health News:College Women's Condom Use Falls During Freshman Year 2Health News:How does cannabis affect working memory? 2Health News:How does cannabis affect working memory? 3Health News:Regular Pap Smear Boosts Cervical Cancer Survival: Study 2Health News:Regular Pap Smear Boosts Cervical Cancer Survival: Study 3Health News:First study of its kind finds no increased risk of heart disease for kidney donors 2
Irrigating Cystotome, Straight, 25 g. Overall length 15 mm. 5/box....
Irrigating Cystotome, formed, 23 g., 12 mm curved tip. Overall length 14 mm. 5/box....
Peribulbar Needle, 23 g. Atkinson style bevel. Overall length 31 mm. 5/box....
Lamellar Blade tip 6600 style, angled bevel up. Dimensions: 11.0 mm (L) x 2.4 mm (W). Cut: 3.7 mm....
Medicine Products: